Form 8-K - Current report:
SEC Accession No. 0001104659-25-108844
Filing Date
2025-11-10
Accepted
2025-11-10 08:00:34
Documents
12
Period of Report
2025-11-09
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K kala-20251109x8k.htm   iXBRL 8-K 41240
  Complete submission text file 0001104659-25-108844.txt   152649

Data Files

Seq Description Document Type Size
2 EX-101.SCH kala-20251109.xsd EX-101.SCH 2677
3 EX-101.LAB kala-20251109_lab.xml EX-101.LAB 15267
4 EX-101.PRE kala-20251109_pre.xml EX-101.PRE 9659
14 EXTRACTED XBRL INSTANCE DOCUMENT kala-20251109x8k_htm.xml XML 4674
Mailing Address 1167 MASSACHUSETTS AVENUE ARLINGTON MA 02476
Business Address 1167 MASSACHUSETTS AVENUE ARLINGTON MA 02476 781-996-5252
KALA BIO, Inc. (Filer) CIK: 0001479419 (see all company filings)

EIN.: 270604595 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38150 | Film No.: 251464423
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)